The Advanced Glycosylation End Product Specific Receptor pipeline drugs market research report outlays comprehensive information on the Advanced Glycosylation End Product Specific Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Advanced Glycosylation End Product Specific Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Respiratory, Immunology, and Oncology which include the indications Alzheimer’s Disease, Cognitive Disorders, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Acute Inflammation, Breast Cancer, and Metastatic Pancreatic Cancer. It also reviews key players involved in Advanced Glycosylation End Product Specific Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Advanced Glycosylation End Product Specific Receptor pipeline targets constitutes close to ten molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 1, 5, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Advanced Glycosylation End Product Specific Receptor overview
Advanced glycosylation end product-specific receptor (AGER) is a cell surface pattern recognition receptor that senses endogenous stress signals with a broad ligand repertoire including advanced glycation end products, S100 proteins, high-mobility group box 1 protein/HMGB1, amyloid beta/APP oligomers, nucleic acids, phospholipids and glycosaminoglycans. Advanced glycosylation end products are nonenzymatically glycosylated proteins that accumulate in vascular tissue with age, and at an accelerated rate in diabetes.
For a complete picture of Advanced Glycosylation End Product Specific Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
